Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: The FIELD study

Diabetes Care

Volumn 35, Issue 2, 2012, Pages 218-225

  Ting, Ru Dee ^a,b   Keech, Anthony C ^a,b   Drury, Paul L ^c   Donoghoe, Mark W ^a   Hedley, John ^d   Jenkins, Alicia J ^a,e   Davis, Timothy M E ^f   Lehto, Seppo ^g   Celermajer, David ^b   Simes, R John ^a   Rajamani, Kushwin ^a,b   Stanton, Kim ^h  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c Auckland Diabetes Centre   (New Zealand)

^d Wairau Hospital   (New Zealand)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g KUOPIO UNIVERSITY HOSPITAL   (Finland)

^h ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FENOFIBRATE; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DIABETIC PATIENT; DISEASE SEVERITY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; STROKE;

AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; FENOFIBRATE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOLIPIDEMIC AGENTS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED;

EID: 84858216690     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1109     Document Type: Article

References (39)

1. World Health Organization. Cardiovascular diseases (CVD) [fact sheet online], 2009. Available from http://www.who.int/mediacentre/factsheets/fs317/ en/index.html. Accessed 3 March 2010
2. Hemmelgarn BR, Manns BJ, Lloyd A, et al.; Alberta Kidney Disease Network. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010;303:423-429
3. Drury PL, Ting R, Zannino D, et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011;54:32-43
4. Keech A, Simes RJ, Barter P, et al.; FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study): randomised controlled trial. Lancet 2005;366:1849-1861
5. Rajamani K, Colman PG, Li LP, et al.; FIELD Study Investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD Study): a prespecified analysis of a randomised controlled trial. Lancet 2009;373:1780-1788
6. Keech AC, Mitchell P, Summanen PA, et al.; FIELD Study Investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD Study): a randomised controlled trial. Lancet 2007;370:1687-1697 (Pubitemid 350100775)
7. Davis TM, Ting R, Best JD, et al.; Fenofibrate Intervention and Event Lowering in Diabetes Study Investigators. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011;54:280-290
8. Abbott Pharmaceuticals. Fenofibrate product information, 2011. Available from www.medicines.org.au/files/smplipid.pdf. Accessed 10 December 2011
9. McPherson R, Frohlich J, Fodor G, Genest J; Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement: recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-927 (Pubitemid 44596492)
10. Ansquer J-C, Dalton RN, Caussé E, Crimet D, Le Malicot K, Foucher C. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis 2008;51:904-913 (Pubitemid 351697561)
11. Ninomiya T, Perkovic V, de Galan BE, et al.; ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20:1813-1821
12. Shahinfar S, Dickson T, Zhang Z, Keane WF, Brenner BM; RENAAL Investigators. Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAALstudy. Kidney Int 2005;67 (Suppl.): S48-S51 (Pubitemid 40019216)
13. Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement fromthe National Kidney Foundation. Am J Kidney Dis 2007;50:169-180 (Pubitemid 47095094)
14. Levey AS, Greene T, Kusek J, Beck G. A simplified equation topredict glomerular filtration rate from serum creatinine (Abstract). J Am Soc Nephrol 2000;11:155A
15. Ikewaki K, Tohyama J, Nakata Y, Wakikawa T, Kido T, Mochizuki S. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men: a nuclear magnetic resonance study. J Atheroscler Thromb 2004;11:278-285
16. Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res 2004;45:174-185 (Pubitemid 38176628)
17. Hottelart C, El Esper N, Rose F, Achard J-M, Fournier A. Fenofibrate increases creatininemia byincreasing metabolic production of creatinine. Nephron 2002;92:536-541
18. Ansquer J-C, Foucher C, Rattier S, Taskinen M-R, Steiner G; DAIS Investigators. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005;45:485-493 (Pubitemid 40341327)
19. Ginsberg HN, Elam MB, Lovato LC, et al.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-1574
20. U.S. Food and Drug Administration. 2011 Meeting materials, endocrinologic and metabolic drugs advisory committee [article online], 2011. Available from http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm252891.htm. Accessed 26 September 2011
21. Jones PH, Goldberg AC, Knapp HR, et al. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. Am Heart J 2010;160:759-766
22. Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol 2009;103:515-522
23. Roth EM, McKenney JM, Kelly MT, et al. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, doubleblind study. AmJ Cardiovasc Drugs 2010;10:175-186
24. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-342 (Pubitemid 38101606)
25. Gaede P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of amultifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591 (Pubitemid 351214285)
26. Cooper ME, Jandeleit-Dahm K, Thomas MC. Targets toretard the progression of diabetic nephropathy. Kidney Int 2005;68:1439-1445 (Pubitemid 43169889)
27. Gaede P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention inpatients with type 2 diabetes mellitus and microalbuminuria: the Steno Type 2 Randomised Study. Lancet 1999;353:617-622 (Pubitemid 29087981)
28. Gerstein HC, Yusuf S, Mann JFE, et al.; Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000;355:253-259 (Pubitemid 30068516)
29. Patel A, MacMahon S, Chalmers J, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572 (Pubitemid 351831357)
30. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713
31. Ismail-Beigi F, Craven T, Banerji MA, et al.; ACCORD Trial Group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010;376:419-430
32. Turner RC, Holman RR, Cull CA, et al.; UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose controlwith sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
33. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
34. Cipher Pharmaceuticals. Fenomax product monograph, 2006. Available from webprod3.hc-sc.gc.ca/dpd-bdpp/indexeng.jsp. Accessed 10 December 2011
35. Abbott Laboratories. Tricor product information [article online], 2010. Available from http://www.rxabbott.com/pdf/tricorpi.pdf. Accessed 16 December 2010
36. Abbott Healthcare Products Limited. Lipantil product information [article online], 2009. Available from http://www.medicines.org.uk/emc/medicine/2567. Accessed 16 December 2010
37. Shionogi Pharma. Triglide product information [article online], 2010. Available from http://www.triglide.com/triglide%20pi.pdf. Accessed 16 December 2010
38. Chudleigh RA, Dunseath G, Evans W, et al. How reliable is estimation of glomerular filtration rate at diagnosis of type 2 diabetes? Diabetes Care 2007;30:300-305 (Pubitemid 46198334)
39. Laboratoires Fournier. Fenofibrate Investigator's Brochure. Daix, France, Laboratoires Fournier Research Centre, 2004